5th World ADC Summit South Korea

Memo

The 5th World ADC Summit South Korea (9-11 June 2026 | Seoul) is Asia's premier meeting dedicated to accelerating next-generation antibody drug conjugate (ADC) development. As part of the broader World Targeted Therapeutics Summit South Korea, it sits alongside the World TPD and Induced Proximity Summit South Korea and the World Bispecifics and T-Cell Engager Summit South Korea, creating a unified hub for cutting-edge targeted therapeutics innovation. The event brings together more than 300 experts from Korean and global biopharma to address the country's rapid shift from biosimilars toward high-value, first- and best-in-class ADCs. With novel payloads, dual-payload platforms, bispecific ADCs, and strategies to overcome Topo-1 resistance at the forefront, the summit provides end-to-end insights across discovery, preclinical and clinical development, and CMC. Attendees gain access to three dedicated ADC content tracks, two pre-conference days, and additional sessions on bispecifics, T-cell engagers, and targeted protein degradation. Featuring 35+ speakers from organizations such as Daiichi Sankyo, Astellas, Pfizer, AbbVie, and Kanaph Therapeutics, the summit offers unmatched opportunities for scientific exchange, partnership building, and technology showcasing. As part of the co-located World Targeted Therapeutics Summit, it plays a central role in establishing South Korea as a rising global hub for precision-driven cancer therapeutics. URLs:Tickets: https://go.evvnt.com/3474355-2?pid=5569Brochure: https://go.evvnt.com/3474355-3?pid=5569 Prices:Drug Developer Pricing - 3 Day Pass (Workshop Day + Conference): USD 2548.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 1849.00,Academic Pricing - 3 Day Pass (Workshop Day + Conference): USD 2298.00,Academic Pricing - 2 Day Pass (Conference Only): USD 1649.00,Service Provider Pricing - 3 Day Pass (Workshop Day + Conference): USD 5198.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3899.00 Speakers: Alireza Tafazzol, Senior Scientist II, AbbVie, Daniel Milano, Senior Director, ADC Process Development and MSAT, AbbVie, Johanna Midelet, Head, Bioconjugation and Chemistry, Abzena, Romain Bertrand, Director, ADC Chemistry, Araris, Yu-Shin Hsu, Research Analyst Lead, Beacon by Hanson Wade, Giorgio Salciarini, Head, Sales and Technical Business Development, BSP Pharmaceuticals, John Flygare, Head of Large Molecule and ADC Innovation, Eli Lilly, Brandon Coyle, Director of Pivotal Process Development, Gilead, Ertan Eryilmaz, Vice President, InduPro, Eugenio Cardenal Vigil, Senior Principal Scientist II CMC Regulatory Affairs, Janssen Biologics, Anette Sommer, Head, R and D, Lonza, Zhaohui Sunny Zhou, Professor and Faculty Fellow, Northeastern University, Chris Neumann, Senior Director, Head of ADC Chemistry, Pfizer, Gregory Szeto, Scientific Director, Pfizer, Matt Levengood, Director, ADC Engineering, Pfizer, Karsten Hartvigsen, Scientist, Servier Symphogen, Olivier Marcq, Senior Vice President, CMC, Tubulis, Marc-Andre Kasper, Vice President, Chemistry and Early Discovery, Tubulis, Jimmy Li, Chief Executive Officer, Wuxi XDC, Rafael Amado, President, Zai Lab, Jinwon Jung, Senior Director, ABL Bio, Nam-Gu Her, Chief Executive Officer, Aimed Bio, Pedro Lee, Head of Biology, CrossPoint Therapeutics, Tae Hwan Kim, Associate Professor, College of Pharmacy, Daegu University, Joseph Kim, Senior Vice President, Kanaph Therapeutics, Shawn (Sang) Hyun Lee, Vice President, Orum Therapeutics, Jin-San Yoo, President, R and D, PharmAbcine, Doo Young Jung, Chief Executive Officer, Pinot Bio, Won Gyun Ahn, Associate Director, Qurient, Shawn Seong, Chief Executive Officer, Shaperon, Jo Hae Park, Head, Business Development and Licensing, TriOar Biotechnology, Michinori Akaiwa, Senior Director and Head of ADC Biologics Engineering, Oncology Research, Astellas, Bin Zou, Founder and Chief Executive Officer, Axcynsis, Dongzhou Jeffrey Liu, Chief Scientific Officer, Head of R and D, Huadong Medicine, Guodu Liu, Professor, Inner Mongolia University, Koji Yashiro, Director, Pacific Business Development and Licensing, Merck and Co, Heidi Wang, Chief Executive Officer, OBI Pharma, David Huang, Senior Director, Head of ADC Enabling Technologies, OBI Pharma, Wei-Han Lee, Senior Director, CMC, OBI Pharma, Yoshitsugu Shitaka, Chief Executive Officer, RealizeEdge, Kaisheng Huang, Chief Operating Officer and Chief Quality Officer, Remegen, Nitin Damle, Executive Vice President and Chief Innovation Officer, Sun Pharma, Gerold Meinhardt, Vice President, Asset and Portfolio Management, Daiichi Sankyo Category: Conferences | Science, Health and Medicine | Oncology Date and Time: 9th June 2026 at 8:00 am to 11th June 2026 at 4:30 pm Venue details: COEX Seeds Le West, Gangseo-gu, Seoul, Korea (South)